Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Trial Profile

Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RECOURSE
  • Sponsors Taiho Oncology
  • Most Recent Events

    • 21 Jan 2017 Results of post-hoc analysis assessing time to grade ≥3 adverse events, presented at the 2017 Gastrointestinal Cancers Symposium
    • 21 Jan 2017 Results of post hoc analysis assessing correlations between onset of neutropenia and survival benefit, presented at the 2017 Gastrointestinal Cancers Symposium
    • 21 Jan 2017 Results analysing quality of life outcomes by using QTWIST method, presented at the 2017 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top